NFKB1 and chronic obstructive pulmonary disease: In conclusion, the present study revealed that amurensin H could ameliorate LPS/CS-induced airway inflammation in vivo and in vitro, suggesting that amurensin H could potentially be useful in COPD airway inflammation treatment, and inhibiting the Syk/NF-κB pathway might be part of its mechanism of action.